
UGN-102 Shows Promising Long-Term Results in Phase 3 ENVISION Trial for LG-IR-NMIBC
UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on developing innovative treatments for urothelial and specialty cancers, has announced the presentation of the Phase 3 ENVISION trial’s efficacy and…












